nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—SLC15A1—Lisinopril—dilated cardiomyopathy	0.801	1	CbGbCtD
Methyldopa—Antinuclear antibody positive—Lisinopril—dilated cardiomyopathy	0.0113	0.0615	CcSEcCtD
Methyldopa—Breast enlargement—Spironolactone—dilated cardiomyopathy	0.00967	0.0527	CcSEcCtD
Methyldopa—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.00714	0.0389	CcSEcCtD
Methyldopa—Vasculitis—Spironolactone—dilated cardiomyopathy	0.00643	0.035	CcSEcCtD
Methyldopa—Gynaecomastia—Spironolactone—dilated cardiomyopathy	0.00561	0.0306	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.0041	0.0224	CcSEcCtD
Methyldopa—Eosinophilia—Spironolactone—dilated cardiomyopathy	0.0039	0.0212	CcSEcCtD
Methyldopa—Bone marrow depression—Lisinopril—dilated cardiomyopathy	0.00379	0.0207	CcSEcCtD
Methyldopa—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00363	0.0198	CcSEcCtD
Methyldopa—Vasculitis—Furosemide—dilated cardiomyopathy	0.0035	0.0191	CcSEcCtD
Methyldopa—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00328	0.0179	CcSEcCtD
Methyldopa—Endocrine disorder—Lisinopril—dilated cardiomyopathy	0.00309	0.0168	CcSEcCtD
Methyldopa—Lightheadedness—Furosemide—dilated cardiomyopathy	0.00305	0.0166	CcSEcCtD
Methyldopa—Haemolytic anaemia—Furosemide—dilated cardiomyopathy	0.00274	0.015	CcSEcCtD
Methyldopa—Vasculitis—Lisinopril—dilated cardiomyopathy	0.00262	0.0143	CcSEcCtD
Methyldopa—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00246	0.0134	CcSEcCtD
Methyldopa—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.00229	0.0125	CcSEcCtD
Methyldopa—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00226	0.0123	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00223	0.0122	CcSEcCtD
Methyldopa—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00219	0.0119	CcSEcCtD
Methyldopa—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00216	0.0118	CcSEcCtD
Methyldopa—Isoetarine—ADRB1—dilated cardiomyopathy	0.00212	0.142	CrCbGaD
Methyldopa—Eosinophilia—Furosemide—dilated cardiomyopathy	0.00212	0.0116	CcSEcCtD
Methyldopa—Pancreatitis—Furosemide—dilated cardiomyopathy	0.0021	0.0114	CcSEcCtD
Methyldopa—Eczema—Lisinopril—dilated cardiomyopathy	0.00207	0.0113	CcSEcCtD
Methyldopa—Haemolytic anaemia—Lisinopril—dilated cardiomyopathy	0.00206	0.0112	CcSEcCtD
Methyldopa—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.00204	0.0111	CcSEcCtD
Methyldopa—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00201	0.0109	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00193	0.0105	CcSEcCtD
Methyldopa—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00184	0.0101	CcSEcCtD
Methyldopa—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00181	0.00984	CcSEcCtD
Methyldopa—Isoetarine—ADRB2—dilated cardiomyopathy	0.00179	0.119	CrCbGaD
Methyldopa—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00178	0.00971	CcSEcCtD
Methyldopa—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00177	0.00965	CcSEcCtD
Methyldopa—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.0017	0.00926	CcSEcCtD
Methyldopa—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00168	0.00916	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00167	0.00913	CcSEcCtD
Methyldopa—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00165	0.00899	CcSEcCtD
Methyldopa—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.00159	0.00867	CcSEcCtD
Methyldopa—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00158	0.00859	CcSEcCtD
Methyldopa—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00157	0.00853	CcSEcCtD
Methyldopa—Angiopathy—Furosemide—dilated cardiomyopathy	0.00156	0.00848	CcSEcCtD
Methyldopa—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00153	0.00835	CcSEcCtD
Methyldopa—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00153	0.00832	CcSEcCtD
Methyldopa—Dizziness—Spironolactone—dilated cardiomyopathy	0.00148	0.00807	CcSEcCtD
Methyldopa—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00148	0.00807	CcSEcCtD
Methyldopa—Flatulence—Furosemide—dilated cardiomyopathy	0.00147	0.00802	CcSEcCtD
Methyldopa—Weight increased—Lisinopril—dilated cardiomyopathy	0.00146	0.00797	CcSEcCtD
Methyldopa—Vomiting—Spironolactone—dilated cardiomyopathy	0.00142	0.00776	CcSEcCtD
Methyldopa—Rash—Spironolactone—dilated cardiomyopathy	0.00141	0.00769	CcSEcCtD
Methyldopa—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00141	0.00769	CcSEcCtD
Methyldopa—Headache—Spironolactone—dilated cardiomyopathy	0.0014	0.00764	CcSEcCtD
Methyldopa—Jaundice—Lisinopril—dilated cardiomyopathy	0.0014	0.00761	CcSEcCtD
Methyldopa—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00136	0.00739	CcSEcCtD
Methyldopa—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00134	0.00729	CcSEcCtD
Methyldopa—Leukopenia—Furosemide—dilated cardiomyopathy	0.00134	0.00728	CcSEcCtD
Methyldopa—Nausea—Spironolactone—dilated cardiomyopathy	0.00133	0.00725	CcSEcCtD
Methyldopa—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00131	0.00714	CcSEcCtD
Methyldopa—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00129	0.00701	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00126	0.00688	CcSEcCtD
Methyldopa—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00119	0.00651	CcSEcCtD
Methyldopa—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00119	0.0065	CcSEcCtD
Methyldopa—Norepinephrine—SLC22A5—dilated cardiomyopathy	0.00118	0.0788	CrCbGaD
Methyldopa—Skin disorder—Furosemide—dilated cardiomyopathy	0.00118	0.00645	CcSEcCtD
Methyldopa—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00117	0.00636	CcSEcCtD
Methyldopa—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00116	0.00632	CcSEcCtD
Methyldopa—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00113	0.00614	CcSEcCtD
Methyldopa—Flatulence—Lisinopril—dilated cardiomyopathy	0.0011	0.00601	CcSEcCtD
Methyldopa—Dopamine—SLC22A5—dilated cardiomyopathy	0.0011	0.0732	CrCbGaD
Methyldopa—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00109	0.00596	CcSEcCtD
Methyldopa—Epinephrine—SLC22A5—dilated cardiomyopathy	0.00107	0.0715	CrCbGaD
Methyldopa—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00105	0.00573	CcSEcCtD
Methyldopa—Constipation—Furosemide—dilated cardiomyopathy	0.00104	0.00568	CcSEcCtD
Methyldopa—Leukopenia—Lisinopril—dilated cardiomyopathy	0.001	0.00546	CcSEcCtD
Methyldopa—Droxidopa—ADRB1—dilated cardiomyopathy	0.000971	0.0646	CrCbGaD
Methyldopa—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000963	0.00525	CcSEcCtD
Methyldopa—Myalgia—Lisinopril—dilated cardiomyopathy	0.000953	0.0052	CcSEcCtD
Methyldopa—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000953	0.0052	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000947	0.00516	CcSEcCtD
Methyldopa—Oedema—Lisinopril—dilated cardiomyopathy	0.000914	0.00498	CcSEcCtD
Methyldopa—Infection—Lisinopril—dilated cardiomyopathy	0.000908	0.00495	CcSEcCtD
Methyldopa—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000897	0.00489	CcSEcCtD
Methyldopa—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000895	0.00488	CcSEcCtD
Methyldopa—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000888	0.00484	CcSEcCtD
Methyldopa—Isoprenaline—ADRB1—dilated cardiomyopathy	0.000882	0.0588	CrCbGaD
Methyldopa—Asthenia—Furosemide—dilated cardiomyopathy	0.000874	0.00476	CcSEcCtD
Methyldopa—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000833	0.00454	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000833	0.00454	CcSEcCtD
Methyldopa—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000821	0.00447	CcSEcCtD
Methyldopa—Norepinephrine—ADRB1—dilated cardiomyopathy	0.000817	0.0544	CrCbGaD
Methyldopa—Droxidopa—ADRB2—dilated cardiomyopathy	0.000816	0.0544	CrCbGaD
Methyldopa—Dizziness—Furosemide—dilated cardiomyopathy	0.000805	0.00439	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000789	0.0043	CcSEcCtD
Methyldopa—Constipation—Lisinopril—dilated cardiomyopathy	0.000781	0.00426	CcSEcCtD
Methyldopa—Vomiting—Furosemide—dilated cardiomyopathy	0.000774	0.00422	CcSEcCtD
Methyldopa—Rash—Furosemide—dilated cardiomyopathy	0.000768	0.00419	CcSEcCtD
Methyldopa—Dermatitis—Furosemide—dilated cardiomyopathy	0.000767	0.00418	CcSEcCtD
Methyldopa—Headache—Furosemide—dilated cardiomyopathy	0.000763	0.00416	CcSEcCtD
Methyldopa—Dopamine—ADRB1—dilated cardiomyopathy	0.00076	0.0506	CrCbGaD
Methyldopa—Isoprenaline—ADRB2—dilated cardiomyopathy	0.000742	0.0494	CrCbGaD
Methyldopa—Epinephrine—ADRB1—dilated cardiomyopathy	0.000741	0.0494	CrCbGaD
Methyldopa—Nausea—Furosemide—dilated cardiomyopathy	0.000723	0.00394	CcSEcCtD
Methyldopa—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000722	0.00394	CcSEcCtD
Methyldopa—Epinephrine—TNF—dilated cardiomyopathy	0.000703	0.0468	CrCbGaD
Methyldopa—Norepinephrine—ADRB2—dilated cardiomyopathy	0.000687	0.0458	CrCbGaD
Methyldopa—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000673	0.00367	CcSEcCtD
Methyldopa—Asthenia—Lisinopril—dilated cardiomyopathy	0.000656	0.00357	CcSEcCtD
Methyldopa—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000625	0.00341	CcSEcCtD
Methyldopa—Epinephrine—ADRB2—dilated cardiomyopathy	0.000623	0.0415	CrCbGaD
Methyldopa—Dizziness—Lisinopril—dilated cardiomyopathy	0.000604	0.00329	CcSEcCtD
Methyldopa—Vomiting—Lisinopril—dilated cardiomyopathy	0.000581	0.00317	CcSEcCtD
Methyldopa—Rash—Lisinopril—dilated cardiomyopathy	0.000576	0.00314	CcSEcCtD
Methyldopa—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000576	0.00314	CcSEcCtD
Methyldopa—Headache—Lisinopril—dilated cardiomyopathy	0.000572	0.00312	CcSEcCtD
Methyldopa—Nausea—Lisinopril—dilated cardiomyopathy	0.000543	0.00296	CcSEcCtD
